Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Common Equity (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Common Equity data on record, last reported at $256.6 million in Q4 2025.

  • For Q4 2025, Common Equity rose 18.8% year-over-year to $256.6 million; the TTM value through Dec 2025 reached $256.6 million, up 18.8%, while the annual FY2025 figure was $256.6 million, 18.8% up from the prior year.
  • Common Equity reached $256.6 million in Q4 2025 per CCCC's latest filing, up from $154.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $416.4 million in Q2 2021 and bottomed at $154.4 million in Q3 2025.
  • Average Common Equity over 5 years is $274.4 million, with a median of $257.4 million recorded in 2024.
  • Peak YoY movement for Common Equity: skyrocketed 408.32% in 2021, then plummeted 36.37% in 2025.
  • A 5-year view of Common Equity shows it stood at $389.6 million in 2021, then fell by 25.76% to $289.2 million in 2022, then dropped by 14.91% to $246.1 million in 2023, then dropped by 12.24% to $216.0 million in 2024, then rose by 18.8% to $256.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $256.6 million in Q4 2025, $154.4 million in Q3 2025, and $174.1 million in Q2 2025.